Viking Therapeutics reports VK2735 maintenance trial keeps up to 97% of weight loss with every-other-week dosing
Bitget2026/09/22 11:05- Viking Therapeutics reported positive topline results from a maintenance study of obesity drug candidate VK2735, following an earlier weekly induction phase.
- Findings showed weight loss could be maintained when dosing shifted to less frequent schedules, supporting broader use beyond weekly injections.
- Weekly dosing over a longer period continued to drive additional weight reduction, suggesting durability without an apparent flattening of effect.
- Safety during maintenance looked favorable, with gastrointestinal side effects broadly comparable to placebo and low treatment discontinuations.
- Results have already been released; an oral-maintenance component is planned for a future part 2 of the study.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Crypto prices
More
